ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.

Author: AndersonGary T, BaridoRichard, BonhausDouglas W, BrannMark R, BrunmarkPer, DavisRobert E, DyssegaardAgnete, GardellLuis R, HacksellUli, JohnsonRobert W, PoundsLinda, TabatabaeiAli, VanoverKimberly E, VeinbergsIsaac

Paper Details 
Original Abstract of the Article :
Dopamine D(2) receptor antagonism contributes to the therapeutic action of antipsychotic drugs (APDs) but also produces undesirable side effects, including extrapyramidal motor deficits, cognitive dulling, and prolactinemia. The introduction of atypical APDs was a significant advancement in the trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1124/jpet.107.121715

データ提供:米国国立医学図書館(NLM)

ACP-103: A Promising New Ally in the Fight Against Schizophrenia

This study investigates the potential of a novel 5-HT(2A) receptor inverse agonist, ACP-103, to improve the efficacy and side-effect profile of antipsychotic drugs. The research demonstrates that ACP-103, when combined with traditional antipsychotics like haloperidol and risperidone, enhances antipsychotic efficacy while reducing adverse effects associated with dopamine D(2) receptor antagonism. These findings suggest that ACP-103 could be a valuable adjunct therapy for schizophrenia, providing a more targeted and potentially safer treatment approach.

A Sun-Drenched Path: New Hope for Schizophrenia Treatment

This study illuminates a sun-drenched path towards potentially improved treatment for schizophrenia. The synergistic effects of ACP-103, when combined with traditional antipsychotics, offer a beacon of hope for patients seeking relief from the debilitating symptoms of this disorder. The research highlights the importance of innovative approaches and the potential for targeted therapies to optimize treatment outcomes and enhance patient well-being.

A Desert Bloom: Reducing Side Effects

This research is like a rare desert bloom, offering a new approach to antipsychotic treatment that could potentially reduce side effects associated with traditional therapies. The study emphasizes the importance of balancing efficacy with safety in the treatment of schizophrenia, aiming to improve both symptom control and patient quality of life.

Dr.Camel's Conclusion

This study explores the potential of ACP-103 as a novel therapeutic agent for schizophrenia, highlighting the promise of synergistic approaches to enhance antipsychotic efficacy while minimizing unwanted side effects. The research offers a glimmer of hope for a future where schizophrenia treatment is both effective and well-tolerated, leading to improved outcomes and a better quality of life for those living with this complex disorder.

Date :
  1. Date Completed 2007-09-20
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

17519387

DOI: Digital Object Identifier

10.1124/jpet.107.121715

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.